Association Between Mineralocorticoid Receptor Antagonist and Mortality in SARS-CoV-2 Patients: A Systematic Review and Meta-Analysis

This systematic review and meta-analysis examined the association between mineralocorticoid receptor antagonist (MRA) therapy and mortality in SARS-CoV-2 patients, involving 1,388,178 subjects, with 80,903 receiving MRA therapy. The study found no significant reduction in mortality associated with MRA therapy, with an odds ratio of 0.387 and a 95% confidence interval of 0.134–1.117 (p = 0.079). Despite MRAs' potential protective effects against tissue fibrosis and inflammation, the results did not support a beneficial impact on mortality rates in COVID-19 patients. The study emphasized the need for larger-scale randomized controlled trials to further explore this relationship.